Brokerages Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $21.13

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $21.1250.

Several equities research analysts recently issued reports on TLX shares. Citigroup lifted their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, April 13th.

Insider Buying and Selling at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch bought 33,435 shares of the stock in a transaction dated Wednesday, April 29th. The stock was bought at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the purchase, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently modified their holdings of the business. Rhumbline Advisers grew its stake in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals during the fourth quarter valued at about $89,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the fourth quarter valued at about $111,000. Vident Advisory LLC bought a new position in shares of Telix Pharmaceuticals during the fourth quarter worth about $204,000. Finally, IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals during the second quarter worth about $213,000.

Telix Pharmaceuticals Price Performance

NASDAQ TLX opened at $10.66 on Friday. The company’s fifty day simple moving average is $9.18 and its 200-day simple moving average is $8.77. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $18.49.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analyst estimates of $421.50 million. As a group, research analysts expect that Telix Pharmaceuticals will post 0.09 earnings per share for the current year.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.